ATLANTA, GA — Despite promise for improving heart failure (HF) in pilot studies, an interatrial shunt (IAS) device did not meet the primary composite efficacy endpoint in a pivotal trial, a result ...

Doctors say that identifying the right patients will be critical to the future of the field. Only time will tell, according ...

PHOENIX -- The functional and quality-of-life benefits of creating a left-to-right shunt in the interatrial septum to offload failing hearts held up over the midterm in a series of small feasibility ...

ATLANTA -- An interatrial shunt failed to provide a clinical benefit to people with heart failure (HF) overall in the RELIEVE-HF trial, though actual harm or benefit seemed to hinge on the patient's ...

Please provide your email address to receive an email when new articles are posted on . Interatrial shunt implant lowered HF hospitalization risk for patients with HFrEF vs. placebo. However, patients ...

BOSTON, MA—This week’s Technology and Heart Failure Therapeutics (THT) 2023 meeting featured more than a dozen talks on interatrial shunts to reduce left atrial pressures and volume overload in heart ...

Results from early clinical evaluation of the Alleviant System to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) was presented today as late-breaking ...

ATLANTA, GA (May 20, 2022) – Results from early clinical evaluation of the Alleviant System to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) was presented ...

Madison Scientific, a Chicago-based startup developing a SmartShunt device, has raised $7 million in seed funding. The private medical device company said in a press release today that funding was ...